Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab and domvanalimab with chemotherapy in metastatic NSCLC
NCT05502237Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2022
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of zimberelimab, domvanalimab in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started Oct 2022; status: active, not recruiting.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05502237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502237.